[Form 4] ATAI Life Sciences N.V. Insider Trading Activity

Rhea-AI Filing Summary

Form 4: Apeiron Investment Group Ltd. and Christian Angermayer reported transactions in ATAI Life Sciences (ATAI). On 08/14/2025 Apeiron acquired 8,675,799 common shares at $2.19 per share. After the transaction Apeiron Investment Group Ltd. beneficially owned 51,045,214 shares (indirect). Apeiron Presight Capital Fund II, L.P. is shown with 1,799,302 shares (indirect). Angermayer is identified as a director and 10% owner.

Positive

• Large disclosed purchase: Apeiron acquired 8,675,799 common shares at $2.19, clearly disclosed on the Form 4
• Clear ownership disclosure: After the transaction Apeiron Investment Group Ltd. reports indirect beneficial ownership of 51,045,214 shares and related fund holdings of 1,799,302 shares
• Proper reporting and signatures: The filing includes authorized signatures from Apeiron and Christian Angermayer

Negative

• None.

Insights

Financial Analyst

TL;DR: Large insider-related acquisition recorded: 8.68M shares bought at $2.19, raising indirect beneficial holdings to 51.05M shares.

The filing documents a sizable non-derivative purchase executed on 08/14/2025 by Apeiron Investment Group Ltd., increasing its indirect beneficial ownership to 51,045,214 shares. The price per share was $2.19 and the transaction code is P, indicating a purchase. The reporting includes related-party holdings via Apeiron Presight Capital Fund II, L.P.

Corporate Governance Expert

TL;DR: Director and 10% owner Christian Angermayer is a reporting person; signatures indicate authorized filing by Apeiron.

The form names Christian Angermayer as both a director and a 10% owner and shows Apeiron Investment Group Ltd. as the reporting entity. Signatures by an Apeiron director and by Angermayer certify the report. The filing appears procedural and consistent with Section 16 reporting requirements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Apeiron Investment Group Ltd.

(Last) (First) (Middle)

66 & 67 BEATRICE, AMERY STREET

(Street)

SILEMA O1 SLM1707

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ATAI Life Sciences N.V. [ ATAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/14/2025		P		8,675,799	A	$2.19	51,045,214	I	By Apeiron Investment Group Ltd.
Common Shares								1,799,302	I	By Apeiron Presight Capital Fund II, L.P.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Apeiron Investment Group Ltd.

(Last) (First) (Middle)

66 & 67 BEATRICE, AMERY STREET

(Street)

SILEMA O1 SLM1707

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Angermayer Christian

(Last) (First) (Middle)

66 & 67 AMERY STREET

(Street)

SILEMA O1 SLM 1707

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

	Apeiron Investment Group Ltd. By: /s/ Mario Frendo, Director	08/18/2025
	/s/ Christian Angermayer	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Apeiron report on ATAI Form 4?

On 08/14/2025 Apeiron Investment Group Ltd. purchased 8,675,799 common shares of ATAI at $2.19 per share (transaction code P).

How many ATAI shares does Apeiron beneficially own after the reported transaction?

Apeiron Investment Group Ltd. reports beneficial ownership of 51,045,214 shares (indirect) following the transaction.

Does the filing identify any related funds and their holdings?

Yes. The filing shows Apeiron Presight Capital Fund II, L.P. with 1,799,302 shares (indirect).

Who signed the Form 4 for these ATAI transactions?

The Form 4 is signed by an Apeiron director (/s/ Mario Frendo) and by Christian Angermayer on 08/18/2025.

What is Christian Angermayer's relationship to ATAI in this filing?

Christian Angermayer is identified as a director and a 10% owner in the filing.